A comprehensive systematic review of 85 studies found synthetic cannabinoids carry 4.4-5.2 times higher psychosis risk than cannabis, with distinct clinical presentations including "spiceophrenia."
Emergency physicians, substance use counselors, drug policy researchers, consumers of synthetic products.
4.4-5.2x higher psychosis risk than cannabis
What the researchers found
Among 85 studies, synthetic cannabinoids showed consistently higher psychosis risk than traditional cannabis (OR 4.4-5.2 for synthetic cannabinoids vs cannabis). Distinct clinical profiles emerged: synthetic cannabinoid "spiceophrenia" featured visual hallucinations (73-84%), agitation (79-91%), and anxiety (62-76%). Key vulnerability factors included pre-existing psychiatric conditions, adolescent exposure, and polysubstance use. Different substance classes showed different neurobiological mechanisms.
Why it matters
While natural cannabis psychosis risk receives significant attention, synthetic cannabinoids pose a dramatically higher risk that is less well recognized. The identification of "spiceophrenia" as a distinct clinical entity with characteristic visual hallucinations and extreme agitation could improve emergency recognition and treatment.
The numbers in context
85 studies included from 684 screened. SC vs cannabis psychosis OR: 4.4-5.2. Spiceophrenia: visual hallucinations 73-84%, agitation 79-91%, anxiety 62-76%. Key risks: prior psychiatric conditions, adolescent use, polysubstance use.
How the study worked
Comprehensive systematic review following PRISMA guidelines across five databases (January 2005-December 2022). Quality assessed using Newcastle-Ottawa Scale and JBI checklist. Of 684 records, 85 met inclusion: case reports (38), retrospective cohorts (25), cross-sectional (10), case-control (7), experimental (3), prospective cohort (2).
What this study cannot tell us
Predominantly case reports and retrospective studies. Publication bias toward severe outcomes. Rapidly evolving synthetic cannabinoid landscape means newer compounds may differ. Polysubstance use complicates attribution. Heterogeneous study designs limit direct comparisons.
How to read the evidence
Strong: comprehensive systematic review of 85 studies with quality assessment, consistent findings across study types.
When this study was published
2025 study (literature 2005-2022)
The bigger picture
Synthetic cannabinoids continue to evolve to evade regulation, and their psychosis risk is dramatically higher than natural cannabis. The finding that they produce a distinct clinical syndrome ("spiceophrenia") argues for separate clinical protocols and public health messaging rather than lumping them with cannabis.
Questions still open
- Are newer synthetic cannabinoids even more psychotogenic than earlier compounds? Would rapid immunoassay detection of synthetic cannabinoids in emergency settings improve outcomes? Should "spiceophrenia" be recognized as a formal diagnostic category?
Common questions
Are synthetic cannabinoids more dangerous than marijuana?
What is "spiceophrenia"?
Read the original research
Novel psychoactive substances and psychosis: A comprehensive systematic review of epidemiology, clinical features, neurobiology, and treatment.
Neuroscience and biobehavioral reviews, 178, 106384
Citation
Ricci, Valerio; Chiappini, Stefania; Martinotti, Giovanni; Maina, Giuseppe. (2025). Novel psychoactive substances and psychosis: A comprehensive systematic review of epidemiology, clinical features, neurobiology, and treatment.. Neuroscience and biobehavioral reviews, 178, 106384. https://doi.org/10.1016/j.neubiorev.2025.106384
Explore the wider topic
- THC Purity and Potency: What the Label Actually Means
- Dab and Concentrate Withdrawal: Why It Hits Harder
- Delta-8 THC: Addiction, Withdrawal, and What We Don't Know
- Edible Addiction and Withdrawal: What Makes It Different
- Edibles and Psychosis: When a Bad Trip Becomes an Emergency
- Vaping vs Smoking vs Edibles: A Harm Reduction Guide
- How Cannabis Products Are Made: From Plant to Concentrate to Edible
- Laced Weed and Contaminated Vapes: Real Risks vs Myths
- Legal vs Street Weed: Quality, Safety, and What You're Actually Smoking
- Quitting Weed Pens and Dabs: Why Concentrates Hit Different
- Quitting Edibles: Is Withdrawal Different from Smoking?
- Sativa vs Indica: The Myth and the Science Behind Cannabis Strain Labels
- Why Is Weed Withdrawal Worse Now Than 20 Years Ago?